Sfoglia per Autore
HLA-Cw6 allele confers sensitivity to efalizumab treatment in psoriasis
2009-01-01 Costanzo, A; Talamonti, M; Botti, E; Spallone, G; Papoutsaki, M; Chimenti, S
Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers
2009-01-01 Costanzo, A; Talamonti, M; Botti, E; Spallone, G; Papoutsaki, M; Chimenti, S
Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy
2009-01-01 Costanzo, A; Talamonti, M; Spallone, G; Botti, E; Chimenti, Ms; Papoutsaki, M; Chimenti, S
NF-κB, IκB Kinase and Interacting Signal Networks in Squamous Cell Carcinomas
2010-01-01 Costanzo, A; Spallone, G; Karin, M
A regulatory feedback loop involving p63 and IRF6 links the pathogenesis of 2 genetically different human ectodermal dysplasias
2010-05-03 Moretti, F; Marinari, B; Lo Iacono, N; Botti, E; Giunta, A; Spallone, G; Garaffo, G; Vernersson Lindahl, E; Merlo, G; Mills, A; Ballarò, C; Alemà, S; Chimenti, S; Guerrini, L; Costanzo, A
Patients with moderate to severe plaque psoriasis: One year after the European medicines agency recommendation of efalizumab suspension
2011-01-01 Talamonti, M; Teoli, M; Botti, E; Spallone, G; Chimenti, S; Costanzo, A
Targeted therapy in nonmelanoma skin cancers
2011-01-01 Spallone, G; Botti, E; Costanzo, A
Efalizumab
2011-01-01 Talamonti, M; Spallone, G; Di Stefani, A; Costanzo, A; Chimenti, S
Developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas
2011-01-01 Botti, E; Spallone, G; Moretti, F; Marinari, B; Pinetti, V; Galanti, S; De Meo, Pd; De Nicola, F; Ganci, F; Castrignano, T; Pesole, G; Chimenti, S; Guerrini, L; Fanciulli, M; Blandino, G; Karin, M; Costanzo, A
TRIM8 and p53: Making the right decision
2012-01-01 Botti, E; Spallone, G; Costanzo, A
Psoriasis, from pathogenesis to therapeutic strategies: IL-21 as a novel potential therapeutic target
2012-08-01 Botti, E; Spallone, G; Caruso, R; Monteleone, G; Chimenti, S; Costanzo, A
Cw6 but not allele LCE3C_LCE3B deletion confers sensitivity to ustekinumab treatment in psoriasis
2012-09-01 Botti, E; Talamonti, M; Spallone, G; Galluzzo, M; Bavetta, M; Teoli, M; Pinetti, V; Costanzo, A
Next generation sequencing technology to explore anti-inflammatory activity of IKKa in psoriasis
2012-09-01 Spallone, G; Botti, E; Talamonti, M; Marinari, B; Pinetti, V; Chimenti, S; Costanzo, A
Etanercept reverses downregulation of inhibitor of nuclear factor kappa-B kinase subunit alpha (IKKa) in psoriasis
2013-01-01 Spallone, G; Botti, E; Pinetti, V; Bavetta, M; Pavlidis, A; Chimenti, S; Costanzo, A
Potential role of HLA-Cw6 in clinical response to anti-tumour necrosis factor alpha and t-cell targeting agents in psoriasis patients
2013-01-01 Talamonti, M; Galluzzo, M; Botti, E; Pavlidis, A; Spallone, G; Chimenti, S; Costanzo, A
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab
2013-08-01 Talamonti, M; Botti, E; Galluzzo, M; Teoli, M; Spallone, G; Bavetta, M; Chimenti, S; Costanzo, A
Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations
2014-11-01 Marinari, B; Botti, E; Bavetta, M; Spallone, G; Zangrilli, A; Talamonti, M; Richetta, A; Chimenti, S; Costanzo, A
Programmed cell death in the skin
2015-01-01 Costanzo, A; Fausti, F; Spallone, G; Moretti, F; Narcisi, A; Botti, E
Leflunomide-induced DRESS syndrome
2016-01-01 Spallone, G; DI STEFANI, A; Sarmati, L; Sordillo, P; Bianchi, L
Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146
2017-01-01 Rapanotti, M; Campione, E; Spallone, G; Orlandi, A; Bernardini, S; Bianchi, L
Data di pubblicazione | Titolo | Autore(i) | Tipo | File |
---|---|---|---|---|
1-gen-2009 | HLA-Cw6 allele confers sensitivity to efalizumab treatment in psoriasis | Costanzo, A; Talamonti, M; Botti, E; Spallone, G; Papoutsaki, M; Chimenti, S | Intervento a convegno | |
1-gen-2009 | Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers | Costanzo, A; Talamonti, M; Botti, E; Spallone, G; Papoutsaki, M; Chimenti, S | Articolo su rivista | |
1-gen-2009 | Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy | Costanzo, A; Talamonti, M; Spallone, G; Botti, E; Chimenti, Ms; Papoutsaki, M; Chimenti, S | Articolo su rivista | |
1-gen-2010 | NF-κB, IκB Kinase and Interacting Signal Networks in Squamous Cell Carcinomas | Costanzo, A; Spallone, G; Karin, M | Contributo in libro | |
3-mag-2010 | A regulatory feedback loop involving p63 and IRF6 links the pathogenesis of 2 genetically different human ectodermal dysplasias | Moretti, F; Marinari, B; Lo Iacono, N; Botti, E; Giunta, A; Spallone, G; Garaffo, G; Vernersson Lindahl, E; Merlo, G; Mills, A; Ballarò, C; Alemà, S; Chimenti, S; Guerrini, L; Costanzo, A | Articolo su rivista | |
1-gen-2011 | Patients with moderate to severe plaque psoriasis: One year after the European medicines agency recommendation of efalizumab suspension | Talamonti, M; Teoli, M; Botti, E; Spallone, G; Chimenti, S; Costanzo, A | Articolo su rivista | |
1-gen-2011 | Targeted therapy in nonmelanoma skin cancers | Spallone, G; Botti, E; Costanzo, A | Articolo su rivista | |
1-gen-2011 | Efalizumab | Talamonti, M; Spallone, G; Di Stefani, A; Costanzo, A; Chimenti, S | Articolo su rivista | |
1-gen-2011 | Developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas | Botti, E; Spallone, G; Moretti, F; Marinari, B; Pinetti, V; Galanti, S; De Meo, Pd; De Nicola, F; Ganci, F; Castrignano, T; Pesole, G; Chimenti, S; Guerrini, L; Fanciulli, M; Blandino, G; Karin, M; Costanzo, A | Articolo su rivista | |
1-gen-2012 | TRIM8 and p53: Making the right decision | Botti, E; Spallone, G; Costanzo, A | Articolo su rivista | |
1-ago-2012 | Psoriasis, from pathogenesis to therapeutic strategies: IL-21 as a novel potential therapeutic target | Botti, E; Spallone, G; Caruso, R; Monteleone, G; Chimenti, S; Costanzo, A | Articolo su rivista | |
1-set-2012 | Cw6 but not allele LCE3C_LCE3B deletion confers sensitivity to ustekinumab treatment in psoriasis | Botti, E; Talamonti, M; Spallone, G; Galluzzo, M; Bavetta, M; Teoli, M; Pinetti, V; Costanzo, A | Intervento a convegno | |
1-set-2012 | Next generation sequencing technology to explore anti-inflammatory activity of IKKa in psoriasis | Spallone, G; Botti, E; Talamonti, M; Marinari, B; Pinetti, V; Chimenti, S; Costanzo, A | Intervento a convegno | |
1-gen-2013 | Etanercept reverses downregulation of inhibitor of nuclear factor kappa-B kinase subunit alpha (IKKa) in psoriasis | Spallone, G; Botti, E; Pinetti, V; Bavetta, M; Pavlidis, A; Chimenti, S; Costanzo, A | Articolo su rivista | |
1-gen-2013 | Potential role of HLA-Cw6 in clinical response to anti-tumour necrosis factor alpha and t-cell targeting agents in psoriasis patients | Talamonti, M; Galluzzo, M; Botti, E; Pavlidis, A; Spallone, G; Chimenti, S; Costanzo, A | Articolo su rivista | |
1-ago-2013 | Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab | Talamonti, M; Botti, E; Galluzzo, M; Teoli, M; Spallone, G; Bavetta, M; Chimenti, S; Costanzo, A | Articolo su rivista | |
1-nov-2014 | Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations | Marinari, B; Botti, E; Bavetta, M; Spallone, G; Zangrilli, A; Talamonti, M; Richetta, A; Chimenti, S; Costanzo, A | Articolo su rivista | |
1-gen-2015 | Programmed cell death in the skin | Costanzo, A; Fausti, F; Spallone, G; Moretti, F; Narcisi, A; Botti, E | Articolo su rivista | |
1-gen-2016 | Leflunomide-induced DRESS syndrome | Spallone, G; DI STEFANI, A; Sarmati, L; Sordillo, P; Bianchi, L | Articolo su rivista | |
1-gen-2017 | Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146 | Rapanotti, M; Campione, E; Spallone, G; Orlandi, A; Bernardini, S; Bianchi, L | Articolo su rivista |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile